There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Maravai Lifesciences Holdings (MRVI – Research Report) with bullish sentiments.
Cytokinetics (CYTK)
In a report released today, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics, with a price target of $56.00. The company’s shares closed last Tuesday at $42.52.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $64.00, implying a 49.2% upside from current levels. In a report issued on January 6, Mizuho Securities also assigned a Buy rating to the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
Maravai Lifesciences Holdings (MRVI)
Goldman Sachs analyst Matthew Sykes maintained a Buy rating on Maravai Lifesciences Holdings today and set a price target of $16.00. The company’s shares closed last Tuesday at $13.70, close to its 52-week low of $12.16.
According to TipRanks.com, Sykes has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Maravai Lifesciences Holdings with a $22.70 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
- Truist healthcare analysts to hold an analyst/industry conference call
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Analysts Line up Their Top Picks for 2023
- 3 “Strong Buy” Stocks to Coast Your Portfolio into 2023
